← Leaderboards
Chunhai Charlie Hao
Emory University
$5,475,176
Attributed
$7,711,753
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,711,753 · 5
By mechanism
R01$5,212,751 · 3
R44$1,999,119 · 1
R41$499,883 · 1
Top collaborators
- Chafiq Hamdouchi4 shared
- Anita Bellail2 shared
- Ho Yin Lo2 shared
Most similar at Emory University
Same institution · by research overlap
- Shi-Yong Sun$12,583,440
- Daniel J Brat$12,411,183
- Keqiang Ye$14,630,495
- Steven A Sloan$8,319,028
- Guy Martin Benian$11,724,694
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsTreatment EfficacyUbiquitinationXenograft ProcedureIn VivoMalignant NeoplasmsCellsUbiquitinLibrariesClinical TreatmentUbiquitin-Protein LigaseGlioblastomaSmall MoleculeDrug KineticsMediatingPharmaceutical PreparationsModificationPharmacotherapyIn VitroClinical TrialsNovel TherapeuticsTechnologyPreclinical DevelopmentBase
Grant awards (17)
Development of BBB-permeable SUMO1 small molecule degraders for glioblastoma therapy.$421,952
R01 · FY2025 · NS · contact PI
Development of Small-Molecule Degraders of APP as the first-in-class drugs for Alzheimer's therapy$499,883
R41 · FY2024 · AG · contact PI
Development of BBB-permeable SUMO1 small molecule degraders for glioblastoma therapy.$445,738
R01 · FY2024 · NS · contact PI
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$979,536
R44 · FY2023 · CA
Development of BBB-permeable SUMO1 small molecule degraders for glioblastoma therapy.$465,410
R01 · FY2023 · NS · contact PI
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$1,019,583
R44 · FY2022 · CA
Development of BBB-permeable SUMO1 small molecule degraders for glioblastoma therapy.$474,563
R01 · FY2022 · NS · contact PI
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy$380,055
R01 · FY2021 · CA · contact PI
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy$379,607
R01 · FY2020 · CA · contact PI
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy$367,808
R01 · FY2019 · CA · contact PI
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy$378,761
R01 · FY2018 · CA · contact PI
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy$359,147
R01 · FY2017 · CA · contact PI
Molecular mechanisms of TRAIL resistance in glioblastoma$293,258
R01 · FY2013 · CA · contact PI
Molecular mechanisms of TRAIL resistance in glioblastoma$311,976
R01 · FY2012 · CA · contact PI
Molecular mechanisms of TRAIL resistance in glioblastoma$311,976
R01 · FY2011 · CA · contact PI
Molecular mechanisms of TRAIL resistance in glioblastoma$300,875
R01 · FY2010 · CA · contact PI
Molecular mechanisms of TRAIL resistance in glioblastoma$321,625
R01 · FY2009 · CA · contact PI